Composition for improving obesity or lipid metabolism comprising rostellularia procumbens extract

Abstract

The present invention relates to a composition for alleviating obesity or improving lipid metabolism, comprising a Rostellularia procumbens extract. The Rostellularia procumbens extract according to the present invention has the effects of inhibiting weight gain and fat accumulation and lowering blood levels of total triglycerides, total cholesterol, and low-density lipoprotein. In addition, the Rostellularia procumbens extract of the present invention, as a natural medicinal agent, can be applied to various products such as pharmaceutical compositions, food compositions, and feed compositions for the prevention, treatment, or alleviation of obesity or for the improvement of lipid metabolism.

Description

Composition for improving obesity or lipid metabolism comprising extract of rattail lily

[0001] This application claims priority to Republic of Korea Patent Application No. 10-2024-0045827, filed March 22, 2024, the entire disclosure of which is incorporated herein by reference.

[0002] The present invention relates to a composition for improving obesity or lipid metabolism comprising an extract of Ligusticum japonica.

[0003]

[0004] Recent economic growth and changes in Western lifestyles have led to significant changes in eating habits. In particular, busy modern people are experiencing an increase in overweight and obesity due to high-calorie diets like fast food and low exercise levels. Obesity is a chronic disease characterized by excessive accumulation of adipose tissue due to energy balance regulation dysfunction or hypernutrition, which increases the morbidity and mortality rates of various diseases. Obesity and related diseases are a common and serious public health problem in the United States and around the world. According to the World Health Organization (WHO), more than one billion adults worldwide are overweight, and at least 3 million of them are clinically obese. Furthermore, the increase is particularly pronounced in the United States and Europe, with an estimated 250,000 deaths annually in Europe and over 25,000 worldwide due to overweight (World Health Organization, Global Strategy on Diet, Physical Activity and Health, 2004).

[0005] Overweight and obesity increase blood pressure and cholesterol levels, contributing to various ailments such as heart disease, diabetes, and arthritis, and increasing the incidence of various adult diseases. Furthermore, overweight and obesity are factors that increase the incidence of various adult diseases such as arteriosclerosis, hypertension, hyperlipidemia, and heart disease not only in adults but also in children and adolescents.

[0006] The present inventors have completed the present invention by experimentally confirming that the extract of the common angelica tree is useful in suppressing weight gain and fat gain and lowering the concentrations of total triglycerides, total cholesterol, and low-density lipoprotein in the blood, as a result of efforts to develop a natural product effective in improving obesity and lipid metabolism.

[0007]

[0008] The purpose of the present invention is to provide a food composition for preventing or improving obesity or improving lipid metabolism, which contains an extract of rattail lily as an effective ingredient.

[0009] In addition, the purpose of the present invention is to provide a pharmaceutical composition for preventing or treating obesity or improving lipid metabolism, which contains an extract of rattail lily as an active ingredient.

[0010] In addition, the purpose of the present invention is to provide a feed composition for preventing or improving obesity or improving lipid metabolism, which contains an extract of rattail lily as an effective ingredient.

[0011] However, the technical problems to be solved by the present invention are not limited to the problems mentioned above, and other problems not mentioned will be clearly understood by those skilled in the art from the description below.

[0012]

[0013] The present invention provides a food composition for preventing or improving obesity or improving lipid metabolism, comprising an extract of rattail lily as an effective ingredient.

[0014] In addition, the present invention provides a pharmaceutical composition for preventing or treating obesity, improving lipid metabolism, or preventing or treating lipid-related metabolic diseases, comprising an extract of the common lily of the valley as an active ingredient.

[0015] The above lipid-related metabolic disease may include one or more diseases selected from the group consisting of hypercholesterolemia, hyperlipidemia, hyperinsulinemia, arteriosclerosis, stroke, dyslipidemia, fatty liver, diabetes, and hypertension.

[0016] In addition, the present invention provides a feed composition for preventing or improving obesity or improving lipid metabolism, which contains an extract of rattail lily as an effective ingredient.

[0017] The above composition can suppress weight gain.

[0018] The above composition can suppress body fat increase.

[0019] The composition can lower the concentration of one or more selected from the group consisting of total triglycerides, total cholesterol and low-density lipoprotein in the blood.

[0020] The above composition can be extracted with a solvent selected from the group consisting of water, organic solvents and mixtures thereof.

[0021] The above organic solvent may be one or more solvents selected from the group consisting of lower alcohols having 1 to 6 carbon atoms, hexane, acetone, ethyl acetate, chloroform, and diethyl ether.

[0022] In addition, the present invention provides a method for preventing or treating obesity, a method for improving lipid metabolism, or a method for preventing or treating lipid-related metabolic diseases, comprising a step of administering or ingesting to a subject a composition containing an extract of rattail lily as an active ingredient.

[0023] In addition, the present invention provides a composition comprising a rattail extract as an active ingredient for use in preventing or treating obesity, improving lipid metabolism, or preventing or treating lipid-related metabolic diseases.

[0024]

[0025] The extract of the present invention inhibits weight gain and fat gain, and lowers blood total triglycerides, total cholesterol, and low-density lipoprotein levels. Furthermore, the extract of the present invention can be applied as a natural medicine to various products, including pharmaceutical compositions, food compositions, and feed compositions for preventing, treating, or improving obesity, or improving lipid metabolism.

[0026]

[0027] Figure 1 is a graph showing the results of confirming the weight gain inhibition effect of the extract of the common angelica tree (CON: normal control group, HFD: high-fat diet, JP 200: 200 mg / kg of the extract of the common angelica tree).

[0028] Figure 2 is a graph showing the results of confirming the effect of suppressing fat increase by the extract of the common lily (CON: normal control group, HFD: high-fat diet group, JP 200: 200 mg / kg of the extract of the common lily; *, p < 0.05; ****, p < 0.0001).

[0029] Figure 3 is a graph showing the results of confirming the inhibitory effect of the extract of the common angelica tree on the concentration of total neutral fat and low-density lipoprotein in the blood (CON: normal control group, HFD: high-fat diet, JP 200: 200 mg / kg of the extract of the common angelica tree; *, p < 0.05; **, p < 0.01; ****, p < 0.0001).

[0030] Figure 4 is a graph showing the results of confirming the lipid accumulation inhibition effect of the extract of the common lily (****, p < 0.0001).

[0031]

[0032] The present inventors completed the present invention by experimentally confirming that an extract of the common angelica tree, a natural product with little or no side effects, is effective in suppressing weight gain and fat gain and lowering blood total triglyceride, total cholesterol, and low-density lipoprotein concentrations.

[0033]

[0034] Hereinafter, the present invention will be described in detail.

[0035] The present invention provides a composition for preventing, treating or improving obesity, or for improving lipid metabolism, or for preventing or treating lipid-related metabolic diseases, comprising an extract of Justicia procumbens L. as an active ingredient.

[0036] The above composition can suppress weight gain.

[0037] The above composition can suppress fat increase.

[0038] The composition can lower the concentration of one or more selected from the group consisting of total triglycerides, total cholesterol and low density lipoprotein (LDL) in the blood.

[0039] The above composition can be extracted with a solvent selected from the group consisting of water, organic solvents and mixtures thereof.

[0040] The above organic solvent may be one or more solvents selected from the group consisting of lower alcohols having 1 to 6 carbon atoms, hexane, acetone, ethyl acetate, chloroform, and diethyl ether.

[0041] The above composition may contain 0.001 to 80 wt% of a rattail extract based on the total weight of the composition.

[0042] The above composition may be a food composition, a health functional food composition, a feed composition, or a pharmaceutical composition.

[0043] The above lipid-related metabolic disease may be one or more diseases selected from the group consisting of hypercholesterolemia, hyperlipidemia, hyperinsulinemia, arteriosclerosis, stroke, dyslipidemia, fatty liver, diabetes, and hypertension.

[0044] In this specification, “prevention” means any act of delaying the onset of obesity or a lipid metabolism-related disease by administering the composition of the present invention, and “treatment” and “improvement” mean any act of improving or beneficially changing the symptoms of obesity or lipid metabolism or a lipid metabolism-related disease by administering the composition of the present invention.

[0045]

[0046] The above-mentioned extract of the rattail plant can be extracted using a polar solvent or / and a non-polar solvent.

[0047] The polar solvent may include at least one selected from the group consisting of (i) water, (ii) alcohol (preferably, methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol, normal-butanol, 1-pentanol, 2-butoxyethanol or ethylene glycol), (iii) acetic acid, (iv) dimethyl-formamide (DMFO), and (v) dimethyl sulfoxide (DMSO). The above nonpolar solvent may include at least one selected from the group consisting of acetone, acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, hexane, 2,2,4-trimethylpentane, decane, cyclohexane, cyclopentane, diisobutylene, 1-pentene, 1-chlorobutane, 1-chloropentane, o-xylene, diisopropyl ether, 2-chloropropane, toluene, 1-chloropropane, chlorobenzene, benzene, diethyl ether, diethyl sulfide, chloroform, dichloromethane, 1,2-dichloroethane, aniline, diethylamine, ether, carbon tetrachloride, and THF.

[0048] More specifically, the extract may be extracted using water, an organic solvent, or a mixture thereof as a solvent, and according to a specific embodiment of the present invention, the extract of the present invention may be obtained by treating ethanol to the rhizome of the rhizome of the rhizome of the rhizome. More preferably, it may be obtained by treating 50 to 100% (v / v) ethanol to the rhizome of the rhizome of the rhizome.

[0049] The above organic solvent may include one or more solvents selected from the group consisting of lower alcohols having 1 to 6 carbon atoms (methanol, ethanol, propanol, butanol, etc.), hexane, acetone, ethyl acetate, chloroform, and diethyl ether.

[0050] In addition, the extract of the above-mentioned rat-tail plant can be prepared into fractions according to a method commonly used in the decomposition of the technology, and as a solvent used to fractionate the extract of the above-mentioned rat-tail plant, at least one selected from the group consisting of water, lower alcohols of C1 to C4, n-hexane, ethyl acetate, acetone, acetonitrile, butyl acetate, 1,3-butylene glycol, methylene chloride, and mixed solvents thereof can be used, but is not limited thereto.

[0051]

[0052] The term 'extract' used herein has the meaning commonly used in the art as a crude extract as described above, but in a broad sense, it also includes a fraction obtained by further fractionating an extract. That is, the extract of the purslane plant includes not only a fraction obtained using the extraction solvent described above, but also a fraction obtained by additionally applying a purification process thereto. For example, a fraction obtained by passing the extract through an ultrafiltration membrane having a certain molecular weight cut-off value, a fraction obtained by separation by various chromatographies (designed for separation according to size, charge, hydrophobicity, or affinity), and other fractions obtained through various additional purification methods are also included in the natural product extract of the present invention.

[0053]

[0054] The extract used in the present invention can be manufactured into a powder form by additional processes such as reduced pressure distillation and freeze drying or spray drying.

[0055] Specifically, the extract can be extracted by adding 5 to 50 times the weight of the extract to water, an organic solvent, or a mixture thereof, and more preferably, 10 to 30 times the weight of the extract, but is not limited thereto. The extraction temperature can be 10 to 150 ℃, and more preferably, 15 to 120 ℃, but is not limited thereto. The extraction time is preferably 1 to 20 hours, and more preferably, 2 to 8 hours, but is not limited thereto. The extraction method may be any of a cold steeping, an ultrasonic extraction, or a reflux cooling extraction method, but is not limited thereto. The number of extractions is preferably 1 to 5, and more preferably, 2 to 3 times of repeated extraction is not limited thereto. Additionally, the extract can be diluted, concentrated, or purified and dried after being diluted or concentrated before use.

[0056]

[0057] The term "comprising as an active ingredient" in this specification means including a sufficient amount to achieve the efficacy or activity of the extract of the common yam. The present invention is a composition extracted from the natural plant material, common yam, and the quantitative upper limit of the common yam extract included in the composition of the present invention can be selected and implemented within an appropriate range by those skilled in the art.

[0058]

[0059] A pharmaceutical composition for preventing or treating obesity, improving lipid metabolism, or preventing or treating lipid-related metabolic diseases, containing extracts of rattail lily as an active ingredient

[0060] The composition of the present invention can be prepared as a pharmaceutical composition.

[0061] When the composition of the present invention is prepared as a pharmaceutical composition, the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier.

[0062] According to a preferred embodiment of the present invention, the composition of the present invention may be a pharmaceutical composition comprising (a) a pharmaceutically effective amount of the above-described rat-tail extract of the present invention; and (b) a pharmaceutically acceptable carrier. The term "pharmaceutically effective amount" as used herein means an amount sufficient to achieve the efficacy or activity of the above-described rat-tail extract.

[0063] Pharmaceutically acceptable carriers are those commonly used in formulations, and include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition to the above ingredients, the pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweetening agents, flavoring agents, emulsifiers, suspending agents, preservatives, and the like. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).

[0064] The pharmaceutical composition of the present invention can be administered orally or parenterally.

[0065] The appropriate dosage of the pharmaceutical composition of the present invention can be prescribed in various ways depending on factors such as the formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity. The general dosage of the active ingredient included in the pharmaceutical composition of the present invention is within the range of 0.001-100 mg / kg / day, preferably 0.01-35 mg / kg / day, based on adults. Administration may be administered once a day or divided into several times. However, the scope of the present invention is not limited by the above dosage.

[0066] The pharmaceutical composition of the present invention can be manufactured in a unit dosage form or can be manufactured by inserting it into a multi-dose container by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method that can be easily performed by a person having ordinary skill in the art to which the present invention pertains. In this case, the formulation may be in the form of a solution, suspension, syrup or emulsion in an oil or aqueous medium, or in the form of an extract, powder, granule, tablet or capsule, and may additionally include a dispersing agent or stabilizer.

[0067]

[0068] Food composition for preventing or improving obesity or improving lipid metabolism, containing extract of rattail lily as an active ingredient

[0069] The composition of the present invention can be provided as a food composition or a health functional food composition. When the composition containing the extract of the present invention as an active ingredient is manufactured as a food composition or a health functional food composition, it includes not only the extract of the present invention as an active ingredient, but also ingredients commonly added during food manufacturing, such as proteins, carbohydrates, fats, nutrients, seasonings, and flavoring agents. Examples of the carbohydrates mentioned above include monosaccharides such as glucose, fructose, etc.; disaccharides such as maltose, sucrose, oligosaccharides, etc.; and polysaccharides such as dextrin, cyclodextrin, etc., and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents, natural flavoring agents [thaumatin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.)] and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when the food composition of the present invention is manufactured into a drink, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, Eucommia extract, jujube extract, licorice extract, etc. may be additionally included in addition to the natural product extract of the present invention.

[0070] The formulation of the above food composition or health functional food composition may be in the form of powder, granules, pills, tablets, capsules, or any other form of general food or beverage.

[0071] There is no particular limitation on the types of the above foods, and examples of foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and all foods in the conventional sense can be included.

[0072] In general, when manufacturing food or beverages, the extract of the rattail plant may be added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, per 100 parts by weight of the raw material. However, in the case of long-term consumption for the purpose of health and hygiene or health control, the amount may be less than the above range. Furthermore, since the present invention utilizes natural substances and thus does not pose any safety issues, it may be used in an amount greater than the above range.

[0073]

[0074] Hereinafter, the present invention will be described in more detail through examples. The objectives, features, and advantages of the present invention will be readily understood through the following examples. The present invention is not limited to the examples described herein and may be embodied in other forms. The examples introduced herein are provided to ensure that those skilled in the art can sufficiently convey the spirit of the present invention. Therefore, the present invention should not be limited by the following examples.

[0075]

[0076] [Manufacturing Example 1] Manufacturing of extract of rattail lily

[0077] The dried whole plant of Justicia procumbens L. purchased from Herb Village Co., Ltd. was subjected to 50% (v / v) ethanol, and the mixture was shaken and stirred at room temperature for 7 days. This process was repeated twice. The mixture was subjected to gravity filtration using Whatman paper filter paper with a film thickness of 0.34 mm and a glass funnel to obtain a filtered extract. The filtered extract was transferred to a round flask, placed in a vacuum evaporator, and concentrated by completely evaporating the solvent under reduced pressure at 35°C to obtain a Justicia procumbens extract.

[0078]

[0079] [Example 1] Confirmation of the weight gain suppression effect of the extract of the common dandelion.

[0080] 57BL / 6J mice (male, 12 weeks old) were obtained from Dooyeol Biotech Co., Ltd. and given a one-week adaptation period, then fed a high-fat diet (high fat diet, 60% fat calorie) for 12 weeks to induce obesity (DIO mice, diet-induced obese mice), while the normal control group was fed a regular diet (standard chow, 13.5% fat calorie). The extract of Liriope japonica was prepared in the form of a liquid suspension using 3% CMC (200 mg / kg) and administered for 8 weeks, and body weight was measured. In addition, to correct for the placebo effect of 3% CMC and the weight loss effect due to administration stress, 3% CMC was orally administered daily to the normal control (CON) group. As a result of the experiment, as shown in Fig. 1, it was confirmed that the extract of Liriope japonica inhibited body weight gain induced by a high-fat diet.

[0081]

[0082] [Example 2] Confirmation of the effect of extracts from the common dandelion on fat accumulation.

[0083] After the administration of the extract of the common ginseng root for a total of 8 weeks in Example 1, the weight of abdominal fat and mesenteric fat was analyzed. As a result of the analysis, as shown in Fig. 2, it was confirmed that the extract of the common ginseng root suppressed fat increase caused by a high-fat diet.

[0084]

[0085] [Example 3] Confirmation of the effect of rattail extract on improving lipid metabolism.

[0086] After the administration of the extract of the common angelica tree for a total of 8 weeks in Example 1 above, the concentrations of total triglycerides and low-density lipoprotein in the blood were analyzed. As a result of the analysis, as shown in Fig. 3, it was confirmed that the extract of the common angelica tree improved lipid metabolism, such as by suppressing the increase in the concentrations of total triglycerides and low-density lipoprotein in the blood caused by a high-fat diet.

[0087]

[0088] [Example 4] Comparison of the lipid accumulation inhibition effects of extracts of the same species of the plant and those of the same species in fat cells.

[0089] The inhibitory effects of Justicia spicigera Schltdl. and Justicia carnea Lindl., which were obtained from the Overseas Biological Materials Center of the Korea Research Institute of Bioscience and Biotechnology, on fat accumulation in preadipocytes were compared. 3T3-L1 preadipocytes were maintained in DMEM (Dulbecco's modified Eagle medium) containing 10% bovine serum (Invitrogen, Carlsbad, CA, USA). Differentiation into adipocytes was induced by adding DMEM containing 5 mg / ml insulin, 0.25 mmol / l dexamethasone, and 0.5 nmol / l 3-isobutyl-α-methylxanthine (IBMX) and 10% bovine serum. Each plant sample was treated with 80 μg / ml at the same time during induction. After two days, the differentiation medium and samples were re-treated every other day, and the cells were maintained for 9 days after the start of differentiation, and the lipid accumulation amount was verified using Oil red O staining. As a result, it was confirmed that lipid accumulation was suppressed only in the group treated with the rattail plant, and a stronger effect was observed compared to the other two congenic plants.

Claims

1. A food composition for preventing or improving obesity or improving lipid metabolism, containing an extract of rattail lily as an active ingredient.

2. In claim 1, The above composition is a food composition characterized in that it suppresses weight gain.

3. In claim 1, The above composition is a food composition characterized in that it suppresses the increase of body fat.

4. In claim 1, A food composition characterized in that the composition lowers the concentration of at least one selected from the group consisting of total neutral fat, total cholesterol, and low density lipoprotein (LDL) in the blood.

5. In claim 1, A food composition characterized in that the composition is extracted with a solvent selected from the group consisting of water, organic solvents, and mixtures thereof.

6. In claim 5, A food composition characterized in that the organic solvent is at least one solvent selected from the group consisting of lower alcohols having 1 to 6 carbon atoms, hexane, acetone, ethyl acetate, chloroform, and diethyl ether.

7. A feed composition for preventing or improving obesity or improving lipid metabolism, containing an extract of rattail lily as an active ingredient.

8. A pharmaceutical composition for preventing or treating obesity, improving lipid metabolism, or preventing or treating lipid-related metabolic diseases, containing an extract of rattail lily as an active ingredient.

9. In claim 8, A pharmaceutical composition characterized in that the lipid-related metabolic disease includes at least one disease selected from the group consisting of hypercholesterolemia, hyperlipidemia, hyperinsulinemia, arteriosclerosis, stroke, dyslipidemia, fatty liver, diabetes, and hypertension.

10. A method for preventing or treating obesity, or a method for improving lipid metabolism, or a method for preventing or treating lipid-related metabolic diseases, comprising a step of administering or ingesting to a subject a composition containing an extract of rattail lily as an active ingredient.

11. Use of a composition containing an extract of rattail lily as an active ingredient for preventing or treating obesity, or for improving lipid metabolism, or for preventing or treating lipid-related metabolic diseases.

Images